Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test whether Adalimumab (at two different doses) can induce
and maintain clinical remission in subjects with active Crohn's disease when compared to
placebo (a substance containing no medication)